- Home
- PLRX vs CAC Comparison
PLRX vs CAC Comparison
Compare PLRX & CAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CAC
- Stock Information
- Founded
- PLRX 2015
- CAC 1875
- Country
- PLRX United States
- CAC United States
- Employees
- PLRX N/A
- CAC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CAC Major Banks
- Sector
- PLRX Health Care
- CAC Finance
- Exchange
- PLRX Nasdaq
- CAC Nasdaq
- Market Cap
- PLRX 680.3M
- CAC N/A
- IPO Year
- PLRX 2020
- CAC 1997
- Fundamental
- Price
- PLRX $11.37
- CAC $45.25
- Analyst Decision
- PLRX Strong Buy
- CAC Hold
- Analyst Count
- PLRX 7
- CAC 3
- Target Price
- PLRX $40.50
- CAC $48.33
- AVG Volume (30 Days)
- PLRX 485.5K
- CAC 87.0K
- Earning Date
- PLRX 02-26-2025
- CAC 01-28-2025
- Dividend Yield
- PLRX N/A
- CAC 3.74%
- EPS Growth
- PLRX N/A
- CAC 21.89
- EPS
- PLRX N/A
- CAC 3.62
- Revenue
- PLRX N/A
- CAC $177,396,000.00
- Revenue This Year
- PLRX N/A
- CAC N/A
- Revenue Next Year
- PLRX N/A
- CAC $10.12
- P/E Ratio
- PLRX N/A
- CAC $12.27
- Revenue Growth
- PLRX N/A
- CAC 10.05
- 52 Week Low
- PLRX $10.22
- CAC $28.62
- 52 Week High
- PLRX $18.00
- CAC $50.07
- Technical
- Relative Strength Index (RSI)
- PLRX 44.60
- CAC 51.55
- Support Level
- PLRX $10.35
- CAC $45.00
- Resistance Level
- PLRX $11.07
- CAC $46.49
- Average True Range (ATR)
- PLRX 0.61
- CAC 1.20
- MACD
- PLRX 0.06
- CAC 0.24
- Stochastic Oscillator
- PLRX 43.50
- CAC 48.77
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.